Tom Milne
Research groups
Websites
-
MRC Molecular Haematology Unit
Research Unit
-
MRC Weatherall Institute of Molecular Medicine
Research Institute
Thomas Milne
PhD
Associate Professor of Haematology
Tom Milne received a PhD in 2005 that was co-supervised by Dr. Hugh Brock (University of British Columbia) and Dr. Jay Hess (University of Pennsylvania, Philadelphia, USA) working on the wild type function of the Mixed Lineage Leukaemia (MLL) gene. Tom went on to do postdoctoral studies at The Rockefeller University (NY, USA) with Dr. C. David Allis where he worked on the epigenetics of MLL leukaemias. He then became a Group Leader in 2010 at the MRC Molecular Haematology Unit (MRC Weatherall Institute of Molecular Medicine, The University of Oxford, Oxford, UK) and became an Associate Professor of Haematology in 2014. The Milne lab's major area of interest is in epigenetics and gene regulation in leukaemia. Patients with mutations in the MLL gene do not respond well to conventional therapies and thus have very poor survival rates. This is likely due to the fact that MLL is a master regulator that modifies the epigenetic information content of a cell. The overall goal of the Milne lab is to use MLL leukaemias as a system to identify and analyze novel epigenetic pathways in leukaemia and to understand how they interact with transcription factor networks. The end goal will be to use this information to identify potentially novel druggable targets.
Key publications
-
Mouse models of MLL leukemia: recapitulating the human disease.
Journal article
Milne TA., (2017), Blood, 129, 2217 - 2223
-
MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.
Journal article
Kerry J. et al, (2017), Cell Rep, 18, 482 - 495
-
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.
Journal article
Benito JM. et al, (2015), Cell Rep, 13, 2715 - 2727
Recent publications
-
LEDGF: a leukemia-specific target.
Journal article
Milne TA., (2018), Blood, 131, 4 - 5
-
The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability.
Journal article
Grey W. et al, (2018), Biochim Biophys Acta, 1865, 105 - 116
-
In situ functional dissection of RNA cis-regulatory elements by multiplex CRISPR-Cas9 genome engineering.
Journal article
Wu Q. et al, (2017), Nat Commun, 8
-
Hepcidin is regulated by promoter-associated histone acetylation and HDAC3.
Journal article
Pasricha S-R. et al, (2017), Nat Commun, 8
-
Mouse models of MLL leukemia: recapitulating the human disease.
Journal article
Milne TA., (2017), Blood, 129, 2217 - 2223
ORCID
0000-0002-0413-4271